Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 Exhibit 3.1
- 3.2 Exhibit 3.2
- 4.1 Exhibit 4.1
- 4.2 Exhibit 4.2
- 10.1.3 Exhibit 10.1.3
- 10.6 Exhibit 10.6
- 10.7.3 Exhibit 10.7.3
- 10.7.4 Exhibit 10.7.4
- 10.10 Exhibit 10.10
- 10.13.2 Exhibit 10.13.2
- 10.23 Exhibit 10.23
- 10.24.1 Exhibit 10.24.1
- 10.24.2 Exhibit 10.24.2
- 10.24.3 Exhibit 10.24.3
- 10.25 Exhibit 10.25
- 10.26 Exhibit 10.26
- 16.1 Exhibit 16.1
- 21.1 Exhibit 21.1
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- Download Excel data file
- View Excel data file
NKGN similar filings
- 30 Oct 23 Regulation FD Disclosure
- 24 Oct 23 Other Events
- 19 Oct 23 Financial Statements and Exhibits
- 5 Oct 23 Index to Financial Statements
- 29 Sep 23 Entry into a Material Definitive Agreement
- 29 Sep 23 Submission of Matters to a Vote of Security Holders
- 22 Sep 23 Entry into a Material Definitive Agreement
Filing view
External links
Exhibit 16.1
October 5, 2023
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read the statements made by NKGen Biotech, Inc. (formerly known as Graf Acquisition Corp. IV) included under Item 4.01 of its Form 8-K dated October 5, 2023. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal on September 29, 2023. We are not in a position to agree or disagree with other statements contained therein.
Very truly yours,
/s/ WithumSmith+Brown, PC
New York, New York